본문

서브메뉴

Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chime...
Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras

상세정보

자료유형  
 학위논문 서양
최종처리일시  
20260202104742
ISBN  
9798290652276
DDC  
500
저자명  
Ahn, Green.
서명/저자  
Targeting Extracellular and Membrane Proteins for Degradation Via Lysosome Targeting Chimeras
발행사항  
[Sl] : Stanford University, 2023
발행사항  
Ann Arbor : ProQuest Dissertations & Theses, 2023
형태사항  
172 p
주기사항  
Source: Dissertations Abstracts International, Volume: 87-01, Section: B.
주기사항  
Advisor: Bertozzi, Carolyn.
학위논문주기  
Thesis (Ph.D.)--Stanford University, 2023.
초록/해제  
요약Targeted protein degradation (TPD) is a promising strategy to remove deleterious proteins for therapeutic benefit and to probe biological pathways. The past two decades has witnessed a surge in development of technologies that rely on intracellular machinery to degrade challenging cytosolic targets. However, these TPD platforms leave the majority of extracellular and membrane proteins untouched. To enable degradation of these classes of proteins, we developed lysosome targeting chimeras (LYTACs) as a general strategy to degrade both secreted and membrane-anchored targets as introduced in Chapter 1.The first lysosome targeting chimeras (LYTACs) targeted extracellular and membrane proteins for degradation by bridging a target protein to the lysosome trafficking receptor, cation-independent mannose-6-phosphate receptor (CI-M6PR). Because CI-M6PR has broad tissue distribution, harnessing a receptor with tissue-restricted expression could mitigate off-target effects and allow tissue-specific degradation. In Chapter 2, we developed "GalNAc-LYTACs" that engage the asialoglycoprotein receptor (ASGPR), a liver-specific lysosomal targeting receptor, to degrade extracellular proteins in a cell type-specific manner. Site-specific conjugation and development of homogeneous LYTAC ligands improved the pharmacokinetic profile of GalNAc-LYTACs in vivo. GalNAc-LYTACs represent an avenue for cell-type restricted protein degradation, and additional discovery of recycling receptors with distinct and exclusive localization would expand the range of tissues or cells that LYTACs can target with selectivity. To address this need, we generated a comprehensive map of receptors that traffic from the plasma membrane to the lysosome across different tissues in mice in Chapter 3. Although extracellular degrader technologies have recently expanded the scope of potential therapeutic targets, no prior work has identified cellular features which enable or inhibit membrane protein degradation. Development of LYTACs as therapeutics would greatly benefit from insight into the factors that govern their activity. In Chapter 4, we conducted a genome-wide CRISPR screen to identify modulators of LYTAC-mediated membrane protein degradation. Our findings inform new design strategies for LYTACs with enhanced degradation activity and elucidate fundamental insights of receptor occupancy and trafficking.
일반주제명  
Plasma
일반주제명  
Glycoproteins
일반주제명  
Antibodies
일반주제명  
Biosynthesis
일반주제명  
Genomes
일반주제명  
Autophagy
일반주제명  
Biology
일반주제명  
Flow cytometry
일반주제명  
Liver cancer
일반주제명  
Cells
일반주제명  
CRISPR
일반주제명  
Recycling
일반주제명  
Medical research
일반주제명  
Pharmacokinetics
일반주제명  
Engineering
일반주제명  
Antigens
일반주제명  
Proteomics
기타저자  
Stanford University.
기본자료저록  
Dissertations Abstracts International. 87-01B.
전자적 위치 및 접속  
로그인 후 원문을 볼 수 있습니다.

MARC

 008260126s2023        us                              c    eng  d
■001000017358723
■00520260202104742
■006m          o    d                
■007cr#unu||||||||
■020    ▼a9798290652276
■035    ▼a(MiAaPQ)AAI32149719
■035    ▼a(MiAaPQ)Stanfordsd354ck8170
■040    ▼aMiAaPQ▼cMiAaPQ
■0820  ▼a500
■1001  ▼aAhn,  Green.
■24510▼aTargeting  Extracellular  and  Membrane  Proteins  for  Degradation  Via  Lysosome  Targeting  Chimeras
■260    ▼a[Sl]▼bStanford  University▼c2023
■260  1▼aAnn  Arbor▼bProQuest  Dissertations  &  Theses▼c2023
■300    ▼a172  p
■500    ▼aSource:  Dissertations  Abstracts  International,  Volume:  87-01,  Section:  B.
■500    ▼aAdvisor:  Bertozzi,  Carolyn.
■5021  ▼aThesis  (Ph.D.)--Stanford  University,  2023.
■520    ▼aTargeted  protein  degradation  (TPD)  is  a  promising  strategy  to  remove  deleterious  proteins  for  therapeutic  benefit  and  to  probe  biological  pathways.  The  past  two  decades  has  witnessed  a  surge  in  development  of  technologies  that  rely  on  intracellular  machinery  to  degrade  challenging  cytosolic  targets.  However,  these  TPD  platforms  leave  the  majority  of  extracellular  and  membrane  proteins  untouched.  To  enable  degradation  of  these  classes  of  proteins,  we  developed  lysosome  targeting  chimeras  (LYTACs)  as  a  general  strategy  to  degrade  both  secreted  and  membrane-anchored  targets  as  introduced  in  Chapter  1.The  first  lysosome  targeting  chimeras  (LYTACs)  targeted  extracellular  and  membrane  proteins  for  degradation  by  bridging  a  target  protein  to  the  lysosome  trafficking  receptor,  cation-independent  mannose-6-phosphate  receptor  (CI-M6PR).  Because  CI-M6PR  has  broad  tissue  distribution,  harnessing  a  receptor  with  tissue-restricted  expression  could  mitigate  off-target  effects  and  allow  tissue-specific  degradation.  In  Chapter  2,  we  developed  "GalNAc-LYTACs"  that  engage  the  asialoglycoprotein  receptor  (ASGPR),  a  liver-specific  lysosomal  targeting  receptor,  to  degrade  extracellular  proteins  in  a  cell  type-specific  manner.  Site-specific  conjugation  and  development  of  homogeneous  LYTAC  ligands  improved  the  pharmacokinetic  profile  of  GalNAc-LYTACs  in  vivo.  GalNAc-LYTACs  represent  an  avenue  for  cell-type  restricted  protein  degradation,  and  additional  discovery  of  recycling  receptors  with  distinct  and  exclusive  localization  would  expand  the  range  of  tissues  or  cells  that  LYTACs  can  target  with  selectivity.  To  address  this  need,  we  generated  a  comprehensive  map  of  receptors  that  traffic  from  the  plasma  membrane  to  the  lysosome  across  different  tissues  in  mice  in  Chapter  3.  Although  extracellular  degrader  technologies  have  recently  expanded  the  scope  of  potential  therapeutic  targets,  no  prior  work  has  identified  cellular  features  which  enable  or  inhibit  membrane  protein  degradation.  Development  of  LYTACs  as  therapeutics  would  greatly  benefit  from  insight  into  the  factors  that  govern  their  activity.  In  Chapter  4,  we  conducted  a  genome-wide  CRISPR  screen  to  identify  modulators  of  LYTAC-mediated  membrane  protein  degradation.  Our  findings  inform  new  design  strategies  for  LYTACs  with  enhanced  degradation  activity  and  elucidate  fundamental  insights  of  receptor  occupancy  and  trafficking.
■590    ▼aSchool  code:  0212.
■650  4▼aPlasma
■650  4▼aGlycoproteins
■650  4▼aAntibodies
■650  4▼aBiosynthesis
■650  4▼aGenomes
■650  4▼aAutophagy
■650  4▼aBiology
■650  4▼aFlow  cytometry
■650  4▼aLiver  cancer
■650  4▼aCells
■650  4▼aCRISPR
■650  4▼aRecycling
■650  4▼aMedical  research
■650  4▼aPharmacokinetics
■650  4▼aEngineering
■650  4▼aAntigens
■650  4▼aProteomics
■690    ▼a0306
■690    ▼a0537
■71020▼aStanford  University.
■7730  ▼tDissertations  Abstracts  International▼g87-01B.
■790    ▼a0212
■791    ▼aPh.D.
■792    ▼a2023
■793    ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17358723▼nKERIS▼z이  자료의  원문은  한국교육학술정보원에서  제공합니다.

미리보기

내보내기

chatGPT토론

Ai 추천 관련 도서


    신착도서 더보기
    최근 3년간 통계입니다.

    소장정보

    • 예약
    • 소재불명신고
    • 나의폴더
    • 우선정리요청
    • 비도서대출신청
    • 야간 도서대출신청
    소장자료
    등록번호 청구기호 소장처 대출가능여부 대출정보
    TF19318 전자도서 대출가능 마이폴더 부재도서신고 비도서대출신청 야간 도서대출신청

    * 대출중인 자료에 한하여 예약이 가능합니다. 예약을 원하시면 예약버튼을 클릭하십시오.

    해당 도서를 다른 이용자가 함께 대출한 도서

    관련 인기도서

    로그인 후 이용 가능합니다.